Investors wiped out over $1 billion of the company's valuation after third-quarter Tryngolza sales reached only $9 million, badly trailing Wall Street's $21 million consensus. In response to the slow commercial uptake, management slashed its full-year sales outlook for the treatment to $50 million, down from an earlier target of $100 million to $110 million. The equity plunged roughly 25% within a few hours of the market open, tumbling from over $39 to under $28. This rapid repricing underscores the immediate financial fallout when commercial rollouts for potential blockbuster drugs stumble.
Key points
Sluggish commercial uptake for Tryngolza has severely undermined near-term revenue expect…: Sluggish commercial uptake for Tryngolza has severely undermined near-term revenue expectations for the potential blockbuster.
Management significantly reduced full-year sales guidance for the drug to $50 million fro…: Management significantly reduced full-year sales guidance for the drug to $50 million from previous highs of $110 million.
The steep stock drop highlights investor sensitivity to commercial launch metrics falling…: The steep stock drop highlights investor sensitivity to commercial launch metrics falling short of Wall Street estimates.
Sources checked by our analysis pipeline: 1
Ionis Pharmaceuticals lost more than $1 billion in market value on Monday after the company slashed sales projections for a triglyceride-lowering drug the biotech and Wall Street analysts believe is a potential blockbuster.
The firm announced that it expects the drug, Tryngolza, to bring in $50 million in sales by the end of this year, compared to Ionis’ previous forecast of $100 to $110 million. Third quarter sales came in at $9 million, well below Wall Street consensus expectations of $21 million during the quarter.
The stock reaction was swift. Shares that traded at more than $39 when the market opened within hours sank below $28, a drop of around 25%.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.
Market activity shows Ferrexpo equity facing downward pressure during today's trading session. Current reporting indicates that trading movement remains negative while additional details concerning the slide have not yet emerged. Observers await further updates to understand the specific drivers behind this downward performance.
Regional market participants drove strong momentum across domestic equities, pushing the Jakarta exchange into firmly positive territory by the closing bell. This solid upward push reflects sustained buying interest throughout the daily trading session. The performance demonstrates continued strength for local shares as market activities wrapped up for the day.